Entropy Neurodynamics (ASX:ENP) Volatility: 52.05% (As of Jun. 24, 2026)


What is Entropy Neurodynamics Volatility?

Entropy Neurodynamics ASX:ENP -3.23% Volatility is 52.05% as of Jun. 24, 2026. The stock has 5 warning signs investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2026-06-24), Entropy Neurodynamics's Volatility is 52.05%.

Entropy Neurodynamics  (ASX:ENP) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Entropy Neurodynamics Volatility Related Terms

ASX:ENP vs VRTX, REGN, ALNY: Volatility Comparison

For the Biotechnology subindustry, Entropy Neurodynamics's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entropy Neurodynamics Volatility vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entropy Neurodynamics's Volatility distribution charts can be found below:

* The bar in red indicates where Entropy Neurodynamics's Volatility falls into.


Entropy Neurodynamics  (ASX:ENP) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * √12
=√ 1/(n-1) ∑(Ri - R')^2 * √12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of 52.05% mean?
Entropy Neurodynamics (ASX:ENP) has a Volatility of 52.05% as of Jun. 24, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Entropy Neurodynamics and its competitors.
Is Entropy Neurodynamics' Volatility too high?
Entropy Neurodynamics' current Volatility is 52.05%.
How does Entropy Neurodynamics' Volatility compare to VRTX and REGN?
Entropy Neurodynamics' Volatility of 52.05% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Entropy Neurodynamics and its competitors. Entropy Neurodynamics's current Volatility is 52.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entropy Neurodynamics stock overvalued right now?
Based on GuruFocus' analysis, Entropy Neurodynamics (ASX:ENP) is currently considered Fairly Valued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.03 — trading right at its estimated fair value. The current Volatility is 52.05%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Entropy Neurodynamics (ASX:ENP), the current Volatility is 52.05% as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entropy Neurodynamics Business Description

Other Exchanges TYPTF:USA
Address 117 Camberwell Road,, Hawthorn East, Suite 1.01, Camberwell, Melbourne, VIC, AUS, 3123
Entropy Neurodynamics Ltd is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The company's lead program is TRP-8803. TRP-8803 is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.